Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Novel Immune Checkpoint Inhibitor Under Study in Advanced NSCLC

By: Cordi Craig
Posted: Friday, December 11, 2020

Guo Gui Sun, MD, of the Tangshan People’s Hospital, China, and colleagues found that the anti–PD-1 monoclonal antibody camrelizumab may prove beneficial for previously treated patients with advanced non–small cell lung cancer (NSCLC) and negative oncogenic drivers. Compared with historical data on camrelizumab, the treatment appeared to have a manageable safety profile while also improving objective response and disease control rates in this patient population. However, further studies with larger sample sizes are needed. The study was during the virtual edition of the 2020 Society for Immunotherapy of Cancer Annual Meeting (Abstract 440) and published in the Journal for ImmunoTherapy of Cancer.

The research team enrolled 29 patients who experienced disease progression during or following platinum-based doublet chemotherapy. The patients were treated with camrelizumab (200 mg) every 3 weeks or in combination with chemotherapy until clinical benefit was no longer observed.

Of the 29 patients, 25 were available for evaluation. The objective response rate was 36% (n = 9), and the disease control rate was 92% (n = 23). None of the patients reached the median progression-free survival threshold. Of note, patients with reactive cutaneous capillary endothelial proliferation had a higher objective response rate than those who did not (60% vs. 28.6%).

Most patients experienced treatment-related adverse events (69%). The most common all-grade adverse events included reactive cutaneous capillary endothelial proliferation (37.9%), pneumonitis (6.9%), and chest congestion (6.9%). Severe treatment-related adverse events were reported in 10.3% of patients.

Disclosure: For study authors’ disclosures, visit jitc.bmj.com.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.